Ranbaxy Malaysia Sdn Bhd, a wholly owned subsidiary of Ranbaxy Laboratories has received the approval from Government of Malaysia for setting up a Greenfield manufacturing facility in Malaysia as an EPP (Entry Point Project).
Ranbaxy will be investing around RM 125 Million ($40 Million) in this project that will provide employment to over 200 people. It will be Ranbaxy's second manufacturing facility in Malaysia.
Ranbaxy Laboratories, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1845.90 |
| Dr. Reddys Lab | 1270.10 |
| Cipla | 1292.00 |
| Zydus Lifesciences | 930.75 |
| Lupin | 2246.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: